Claritev (NYSE:CTEV) CEO Travis Dalton Purchases 1,950 Shares of Stock

Claritev (NYSE:CTEV) CEO Travis Dalton bought 1,950 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average price of $38.48 per share, for a total transaction of $75,036.00. Following the transaction, the chief executive officer owned 52,322 shares of the company’s stock, valued at $2,013,350.56. The trade was a 3.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Travis Dalton also recently made the following trade(s):

• On Thursday, August 27th, Travis Dalton bought 4,500 shares of Claritev stock. The stock was purchased at an average cost of $38.81 per share, with a total value of $174,645.00.

Claritev Stock Performance

Shares of CTEV opened at $39.63 on Tuesday. The stock has a fifty day moving average of $31.43 and a two-hundred day moving average of $24.87. The company has a market capitalization of $671.73 million, a PE ratio of -2.33 and a beta of 0.74. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $74.07.

Claritev (NYSE:CTEV) last posted its quarterly earnings data on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.10) by $5.51. The business had revenue of $257.48 million for the quarter. As a group, equities research analysts forecast that Claritev will post -15.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CTEV. Public Investment Fund purchased a new stake in Claritev during the second quarter worth approximately $43,703,438. Arini Captial Management Ltd purchased a new position in shares of Claritev in the 4th quarter valued at $64,291,000. Beach Point Capital Management LP lifted its holdings in shares of Claritev by 77.4% during the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock valued at $32,276,000 after acquiring an additional 329,424 shares in the last quarter. AXQ Capital LP acquired a new position in shares of Claritev during the 4th quarter valued at $223,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Claritev during the 3rd quarter worth $187,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on CTEV shares. Citigroup restated a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Claritev in a report on Monday, August 10th. Wells Fargo & Company increased their price objective on shares of Claritev from $22.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 12th. Wall Street Zen raised shares of Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Barclays restated an “overweight” rating and issued a $40.00 target price (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Finally, Canaccord Genuity Group increased their price target on shares of Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Claritev presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.